Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:51:31.130Z.
Calculation as of: 2026-10-06T21:51:31.130Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5259cb07e2fbb96f0e8f0a81153900e7454c243d03e5865b91db876a0b9f3ffb
PE RATIO
N/A
Market Cap
$426.51M
PE Ratio
N/A
TTM Avg
193.87
3Y Avg
193.87
5Y Avg
193.87
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $418.95M | N/A | N/A | N/A | N/A |
| Prothena Corporation plc (PRTA)vs › | $419.87M | N/A | 33.09 | 33.09 | 33.09 |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A | 7.35 | 7.35 | 7.35 |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | N/A | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | N/A | 138.05 | 184.03 | 168.06 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | 193.87 | 193.87 | 193.87 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.00M | 9.54 | 9.86 | 9.86 | 9.86 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.73
Forward EPS (Est.)
$-0.78
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
